reverse-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-10. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Important branches today are the tourism industry with TUI AG in Hanover, one of Europe's largest travel companies, as well as trade and telecommunications. Hanover is one of Germany's main hubs for insurance and financial-services companies, for example Talanx and Hannover Re. In October 2018, the Lower Saxony unemployment rate stood at 5.0% and was marginally higher than the national average.
Link rot (also called link death, link breaking, or reference rot) is the phenomenon of hyperlinks tending over time to cease to point to their originally targeted file, web page, or server due to that resource being relocated to a new address or becoming permanently unavailable. A link that no longer resolves at the intended target may be called broken or dead. Link rot can be avoided by designing stable and clean URLs, avoiding deep linking, and the use of web archives. The rate of link rot is a subject of study and research due to its significance to the internet's ability to preserve information. Estimates of that rate vary dramatically between studies. Information professionals have warned that link rot could make important archival data disappear, potentially impacting the legal system and scholarship.
=== Variable volume reactions === In some reactions the reactants and the products have significantly different densities. Consequently, as the reaction proceeds the volume of the reaction changes. This variable volume adds terms to the design equations. Taking this volume change into consideration the volume of the reaction becomes:
Sources: en.wikipedia.org
Fast growing microorganisms such as bacteria and yeast have a high concentration of nucleic acid, notably RNA. Levels must be limited in the diets of monogastric animals to <50 g per day. Ingestion of purine compounds arising from RNA breakdown leads to increased plasma levels of uric acid, which can cause gout and kidney stones. Uric acid can be converted to allantoin, which is excreted in urine. Nucleic acid removal is not necessary from animal feeds but is from human foods (humans have lost parts of the uric acid catabolic pathway during their evolution). This problem can be remediated, however. One common method consists in a heat treatment which kills the cells, inactivates proteases and allows endogenous RNases to hydrolyse RNA with release of nucleotides from cell to culture broth.
== Clinical signs == Many signs are associated with PPID, but only a subset of these is displayed in any single horse. Some horses may present with chronic laminitis without other overt signs of the disease.
===== Finasteride ===== Finasteride is used to treat male pattern hair loss. Treatment provides about 30% improvement in hair loss after six months of treatment, and effectiveness only persists as long as the drug is taken. There is no good evidence for its use in women. It may cause gynecomastia, erectile dysfunction and depression.
and above a critical temperature, the self-assembly process will become progressively less likely to occur and spontaneous self-assembly will not happen. The self-assembly is governed by the normal processes of nucleation and growth. Small assemblies are formed because of their increased lifetime as the attractive interactions between the components lower the Gibbs free energy. As the assembly grows, the Gibbs free energy continues to decrease until the assembly becomes stable enough to last for a long period of time. The necessity of the self-assembly to be an equilibrium process is defined by the organization of the structure which requires non-ideal arrangements to be formed before the lowest energy configuration is found. Kinetics The ultimate driving force in self-assembly is energy minimization and the corresponding evolution towards equilibrium, but kinetic effects can also play a very strong role. These kinetic effects, such as trapping in metastable states, slow coarsening kinetics, and pathway-dependent assembly, are often viewed as complications to be overcome in, for example, the formation of block copolymers. Amphiphile self-assembly is an essential bottom-up approach of fabricating advanced functional materials. Self-assembled materials with desired structures are often obtained through thermodynamic control. Here, we demonstrate that the selection of kinetic pathways can lead to drastically different self-assembled structures, underlining the significance of kinetic control in self-assembly.
Sources: en.wikipedia.org
==== MeSH D13.695.740 – pyrimidine nucleotides ==== MeSH D13.695.740.050 – apurinic acid MeSH D13.695.740.246 – cytosine nucleotides MeSH D13.695.740.246.050 – arabinofuranosylcytosine triphosphate MeSH D13.695.740.246.115 – cyclic cmp MeSH D13.695.740.246.150 – cytidine diphosphate MeSH D13.695.740.246.150.180 – cytidine diphosphate choline MeSH D13.695.740.246.150.210 – cytidine diphosphate diglycerides MeSH D13.695.740.246.370 – cytidine monophosphate MeSH D13.695.740.246.370.250 – cytidine monophosphate n-acetylneuraminic acid MeSH D13.695.740.246.400 – cytidine triphosphate MeSH D13.695.740.246.425 – deoxycytosine nucleotides MeSH D13.695.740.246.425.300 – deoxycytidine monophosphate MeSH D13.695.740.600 – pyrimidine dimers MeSH D13.695.740.706 – thymine nucleotides MeSH D13.695.740.706.788 – thymidine monophosphate MeSH D13.695.740.850 – uracil nucleotides MeSH D13.695.740.850.210 – deoxyuracil nucleotides MeSH D13.695.740.850.210.200 – fluorodeoxyuridylate MeSH D13.695.740.850.600 – uridine diphosphate MeSH D13.695.740.850.600.677 – uridine diphosphate sugars MeSH D13.695.740.850.600.677.100 – uridine diphosphate n-acetylgalactosamine MeSH D13.695.740.850.600.677.120 – uridine diphosphate n-acetylglucosamine MeSH D13.695.740.850.600.677.150 – uridine diphosphate n-acetylmuramic acid MeSH D13.695.740.850.600.677.300 – uridine diphosphate galactose MeSH D13.695.740.850.600.677.350 – uridine diphosphate glucose MeSH D13.695.740.850.600.677.375 – uridine diphosphate glucuronic acid MeSH D13.695.740.850.600.677.800 – uridine diphosphate xylose MeSH D13.695.740.850.877 – uridine monophosphate MeSH D13.695.740.850.877.500 – sofosbuvir MeSH D13.695.740.850.950 – uridine triphosphate
During character creation, each upgrade costs one point. The upgrade cost increases as the game progresses. Each ability can be raised from zero to five, and it is impossible to accrue enough experience points to complete every skill (allowing the player to specialize or balance their character). Experience points are gained by completing quests, finding items, or unlocking secret paths rather than killing enemies and are used to increase or unlock the character's statistics and abilities. The game features a main story and optional side quests that can be completed at any time; the player can move between the available areas at will to revisit locations, characters, or merchants. The player's clan affects their skills and powers. Although the attractive Toreadors receive bonuses for seduction and persuasion, opening additional dialogue options, they are physically weak; the Nosferatu are forced to travel in the shadows or through sewers to avoid alerting humans but receive bonuses to their intelligence and computer skills, which enables access to more information. The Malkavians have different dialogue options, reflecting their inherent insanity. Upgrading some skills provides additional dialogue options; attractive and charismatic characters seduce to get their way, aggressive characters threaten, and others persuade their targets to cooperate.
== Side effects == A press release by GlaxoSmithKline in February 2007 noted that there is a greater incidence of fractures of the upper arms, hands and feet in female diabetics given rosiglitazone compared with those given metformin or glyburide. The information was based on data from the ADOPT trial. Following release of this statement, Takeda Pharmaceutical Company, the developer of pioglitazone (sold as Actos in many markets) admitted that it has similar implications for female patients. The risk of hypoglycemia is low in the absence of other drugs that lower blood glucose. Pioglitazone can cause fluid retention and peripheral edema. As a result, it may precipitate congestive heart failure (which worsens with fluid overload in those at risk). It may cause anemia. Mild weight gain is common due to increase in subcutaneous adipose tissue. In studies, patients on pioglitazone had an increased proportion of upper respiratory tract infection, sinusitis, headache, myalgia and tooth problems. Chronic administration of the drug has led to occasional instances of cholestatic hepatitis, reversible upon drug discontinuation. On 30 July 2007, an Advisory Committee of the Food and Drug Administration concluded that the use of rosiglitazone for the treatment of type 2 diabetes was associated with a greater risk of "myocardial ischemic events" when compared to placebo, but when compared to other diabetes drugs, there was no increased risk. Pioglitazone is currently being reviewed.
an L-amino acid + H2O + O2 ⇌ a 2-oxo acid + NH3 + H2O2 The enzyme was first described in 1944 by A. Zeller and A. Maritz. Not only are LAAOs quite variable in terms of molecular mass, they also vary widely regarding stability. In a similar vein, this enzyme performs in a myriad of biological activities including apoptosis-induction, edema-induction, hemorrhaging, and inhibition or induction of platelet aggregation. As suggested by the name of the family, LAAOs are flavoenzymes which function to catalyze the stereospecific oxidative deamination of an L-amino acid. The three substrates of the enzymatic reaction are an L-amino acid, water, and oxygen. The products are the corresponding α-keto acid (2-oxo acid), ammonia, and hydrogen peroxide. One example of the enzyme in action occurs with the conversion L-alanine into pyruvic acid (2-oxopropanoic acid):
=== Blotting === Western blotting can be used in order to quantify the abundance of certain proteins. By using antibodies specific to the protein of interest, it is possible to probe for the presence of specific proteins from a mixture of proteins.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.